CalciMedica, Inc. 8-K

What Happened
CalciMedica, Inc. filed an 8-K on July 7, 2026 reporting that on July 2, 2026 the Board increased from seven to eight directors and appointed Evgeny Zaytsev, M.D., Ph.D., as a Class I director effective immediately. Dr. Zaytsev’s term expires at the 2027 annual meeting. On the same date, director Fred Middleton notified the Board he intends to retire effective at the Company’s 2026 annual meeting; upon his retirement the Board will return to seven directors.

Key Details

• Appointment date: July 2, 2026; Dr. Evgeny Zaytsev named Class I director (term through 2027 annual meeting).
• Director compensation: $40,000 annual cash retainer (prorated) plus an option for 20,000 shares vesting monthly over three years from July 2, 2026, subject to continuous service.
• Governance/agreements: Dr. Zaytsev will sign the Company’s standard director indemnity agreement; no related-person transactions or selection arrangements were reported.
• Retirement: Fred Middleton’s retirement is effective at the 2026 annual meeting and is not due to any disagreement with the Company.

Why It Matters
This 8‑K reports routine board-level changes: a new director was added and granted standard non-employee director pay (cash + equity), while a sitting director plans to retire. For investors, the items are governance updates that may affect board composition and oversight but do not report operational or financial changes. The equity grant aligns the new director’s incentives with shareholders; there are no disclosed conflicts or special arrangements.